Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Tholouli, Eleni  [Clear All Filters]
Journal Article
Maffini E, Ngoya M, Galimard J-E, Harbi S, Kröger N, Platzbecker U, Sengeloev H, Craddock C, Potter V, Choi G, et al. Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2023.
Radujkovic A, Dietrich S, Blok H-J, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant. 2019.
Duque-Afonso J, Finke J, Labopin M, Craddock C, Protheroe R, Kottaridis P, Tholouli E, Byrne JL, Orchard K, Salmenniemi U, et al. Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2022.
Moukalled N, Labopin M, Versluis J, Socié G, Blaise D, Salmenniemi U, Rambaldi A, Gedde-Dahl T, Tholouli E, Kröger N, et al. Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1-mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukem. Am J Hematol. 2024.
Wright PA, van de Pasch LAL, Dignan FL, Kichula KM, Pollock NR, Norman PJ, Marchan E, Hill L, Vandelbosch S, Fullwood C, et al. Donor KIR2DL1 allelic polymorphism influences post-haematopoietic progenitor cell transplantation outcomes in the T cell depleted and reduced intensity conditioning setting. Transplant Cell Ther. 2024.
Beksac M, Eikema D-J, Koster L, Hulin C, Poire X, Hamladji R-M, Gromek T, Bazarbachi A, Ozkurt ZNur, Pabst T, et al. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2024.
Ahmedzai SH, Snowden JA, Ashcroft AJohn, Cairns DAllan, Williams C, Hockaday A, Cavenagh JD, Ademokun D, Tholouli E, Allotey D, et al. Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma. J Clin Oncol. 2019:JCO1801006.
Loke J, McCarthy N, Jackson AE, Siddique S, Hodgkinson A, Mason J, Crawley CR, Gilleece M, Peniket AJ, Protheroe R, et al. Posttransplant MRD and T-cell chimerism status predict outcomes in patients allografted with AML/MDS. Blood Adv. 2023.